Gsk (GSK) EBT Margin (2009 - 2026)

Gsk (GSK) has 18 years of EBT Margin data on file, last reported at 15.58% in Q3 2026.

• For the quarter ending Q3 2026, EBT Margin changed N/A year-over-year to 15.58%; the trailing twelve-month figure through Sep 2026 stood at 13.9% (changed N/A YoY), and the FY2025 full-year result was 22.66%, up 1157.0% from the prior year.
• EBT Margin was 15.58% for Q3 2026 at Gsk, up from 4.21% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 29.12% in Q1 2022 to a low of 0.8% in Q3 2024.
• A 5-year average of 19.91% and a median of 21.18% in 2022 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin slumped 2118 bps in 2024 and surged 2794 bps in 2025, its largest moves.
• Gsk's EBT Margin stood at 21.18% in 2022, then soared by 30 bps to 27.56% in 2023, then sank by 32 bps to 18.69% in 2024, then slumped by 35 bps to 12.23% in 2025, then gained by 27 bps to 15.58% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 15.58% in Q3 2026, 4.21% in Q2 2026, and 28.1% in Q1 2026.